

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claim 1 (Currently Amended) A method of diagnosis of stroke or the possibility thereof in a subject suspected of suffering from stroke, which comprises determining the concentration of at least one polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I in a sample of body fluid ~~taken~~ obtained from the subject.

Claim 2 (Currently Amended) The method of claim 1, wherein ~~A method according to Claim 1, in which~~ the polypeptide is differentially contained in the body fluid of stroke-affected subjects and non-stroke-affected subjects, and the method includes determining whether the concentration of polypeptide in the sample is consistent with a diagnosis of stroke.

Claim 3 (Currently Amended) The method of claim 1, wherein ~~A method according to Claim 1 or 2, in which~~ an antibody to the polypeptide is used in ~~the determination~~ determining of the concentration of the polypeptide.

Claim 4 (Currently Amended) The method of claim 1, wherein ~~A method according to any of Claims 1 to 3, in which~~ the body fluid is cerebrospinal fluid, plasma, serum, blood, tears or urine.

Claim 5 (Currently Amended) The method of claim 1, wherein ~~A method according to Claims 1 to 4, in which~~ the determination of the concentration of the polypeptide is used to determine whether a diagnosed stroke is of the ischaemic or haemorrhagic type.

Claim 6 (Currently Amended) The method of claim 1, further comprising ~~A method according to any of Claims 1 to 5, which comprises~~ subjecting a sample of body fluid ~~taken~~ obtained from the subject to mass spectrometry, ~~thereby~~ to determine a test amount of the polypeptide in the sample, wherein the polypeptide is differentially contained in the body fluid of stroke-affected subjects and non-stroke-affected subjects; and determining whether the test amount is consistent with a diagnosis of stroke.

Claim 7 (Currently Amended) The method of claim 1, wherein ~~A method according to any of Claims 1 to 6, in which~~ the polypeptide is present in the body fluid of stroke-affected subjects and not present in the body fluid of non-stroke-affected subjects, whereby the presence of the polypeptide in a body fluid sample is indicative of stroke.

Claim 8 (Currently Amended) The method of claim 1, wherein ~~A method according to any of Claims 1 to 6, in which~~ the polypeptide is not present in the body fluid of stroke-affected subjects and present in the body fluid of non-stroke-affected subjects, whereby the non-presence of the polypeptide in a body fluid sample is indicative of stroke.

Claim 9 (Currently Amended) The method of claim 6, wherein ~~A method according to any of Claims 6 to 8, in which~~ the mass spectrometry is laser desorption/ionization mass spectrometry.

Claim 10 (Currently Amended) The method of claim 6, wherein ~~A method according to any of Claims 6 to 9, in which~~ the sample is adsorbed on a probe having an immobilised metal affinity

capture (IMAC), hydrophobic, strong anionic or weak cationic exchange surface capable of binding the polypeptide.

Claim 11 (Currently Amended) The method of claim 6, wherein ~~A method according to any of Claims 6 to 10, in which~~ the polypeptide is determined by surface-enhanced laser desorption/ionization (SELDI) and time of flight mass spectrometry (TOF-MS).

Claim 12 (Currently Amended) The method of claim 1, wherein ~~A method according to any of Claims 1 to 11, in which~~ a plurality of peptides is determined in the sample.

Claims 13 - 22 (Canceled)

Claim 23 (Original) An assay device for use in the diagnosis of stroke, which comprises a solid substrate having a location containing a material which recognizes, binds to or has affinity for a polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I.

Claim 24 (Currently Amended) The assay device of claim 23, wherein ~~An assay device according to Claim 23, in which~~ the solid substrate has plurality of locations each respectively containing a material which recognizes, binds to or has affinity for a polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I.

Claim 25 (Currently Amended) The assay device of claim 23, wherein ~~An assay device according to Claim 23 or 24, in which~~ the material is an antibody or antibody chip.

Claim 26 (Currently Amended) The assay device of claim 25, comprising ~~An assay device according to Claim 25, which~~ has a unique addressable location for each antibody, thereby to permit an assay readout for each individual polypeptide or for any combination of polypeptides.

Claim 27 (Currently Amended) The assay device of claim 25, wherein the antibody comprises ~~An assay device according to any of Claims 23 to 26, including~~ an antibody to Apo C-III.

Claim 28 (Currently Amended) The assay device of claim 25, wherein the antibody comprises ~~An assay device according to any of Claims 23 to 26, including~~ an antibody to Serum Amyloid A.

Claim 29 (Currently Amended) The assay device of claim 25, wherein the antibody comprises ~~An assay device according to any of Claims 23 to 26, including~~ an antibody to Apo C-I.

Claim 30 (Currently Amended) The assay device of claim 25, wherein the antibody comprises ~~An assay device according to any of claims 23 to 26, including~~ an antibody to Antithrombin III.

Claim 31 (Currently Amended) The assay device of claim 25, wherein the antibody comprises ~~An assay device according to any of Claims 23 to 26, including~~ an antibody to Apo A-I.

Claim 32 (Original) A kit for use in diagnosis of stroke, comprising a probe for receiving a sample of body fluid, and for placement in a mass spectrometer, thereby to determine a test amount of a polypeptide in the sample, wherein the polypeptide is selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I, or any combination thereof.

Claim 33 (Currently Amended) The kit of claim 32, wherein ~~A kit according to Claim 32, in which~~ the probe contains an adsorbent for adsorption of the polypeptide.

Claim 34 (Currently Amended) The kit of claim 33 ~~A kit according to Claim 33,~~ further comprising a washing solution for removal of unbound or weakly bound materials from the probe.